[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Ocugen Inc (OCGN)

Ocugen Inc (OCGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 464,581
  • Shares Outstanding, K 339,110
  • Annual Sales, $ 4,410 K
  • Annual Income, $ -67,850 K
  • EBIT $ -69 M
  • EBITDA $ -65 M
  • 60-Month Beta 2.21
  • Price/Sales 100.66
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 135.61% (+7.85%)
  • Historical Volatility 45.65%
  • IV Percentile 69%
  • IV Rank 14.44%
  • IV High 544.02% on 11/14/25
  • IV Low 66.66% on 07/21/26
  • Expected Move (DTE 9) 0.2040 (14.52%)
  • Put/Call Vol Ratio 0.05
  • Today's Volume 746
  • Volume Avg (30-Day) 1,203
  • Put/Call OI Ratio 0.16
  • Today's Open Interest 70,151
  • Open Int (30-Day) 68,979
  • Expected Range 1.2010 to 1.6090

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $-0.06
  • Number of Estimates 3
  • High Estimate $-0.04
  • Low Estimate $-0.07
  • Prior Year $-0.07
  • Growth Rate Est. (year over year) +14.29%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.1700 +19.66%
on 07/29/26
1.4800 -5.41%
on 07/15/26
-0.0700 (-4.76%)
since 07/10/26
3-Month
1.1600 +20.69%
on 06/16/26
1.6899 -17.15%
on 06/30/26
-0.0700 (-4.76%)
since 05/12/26
52-Week
0.9800 +42.86%
on 08/20/25
2.7250 -48.62%
on 03/17/26
+0.3700 (+35.92%)
since 08/12/25

Most Recent Stories

More News
Ocugen: Q2 Earnings Snapshot

Ocugen: Q2 Earnings Snapshot

OCGN : 1.4000 (+2.19%)
Ocugen Provides Business Update with Second Quarter 2026 Financial Results

Conference Call and Webcast Today at 8:30 a.m. ET Received U.S. Food and Drug Administration (FDA) clearance to initiate OCU410 Phase 3 trial for geographic atrophy (GA), secondary to dry age-related...

OCGN : 1.4000 (+2.19%)
Ocugen: Gene Therapy Pipeline Meets Reality in Thursday's Report

Barchart Research What to Expect from OCGN Earnings OCGN Generated August 5, 2026 Current Price $1.2800 EPS Estimate $$-0.05 Consensus Rating Strong Buy Average Move 6.03% Ocugen: Gene Therapy Pipeline...

OCGN : 1.4000 (+2.19%)
Ocugen to Participate in Upcoming August Investor Conferences

MALVERN, Pa., July 31, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the...

OCGN : 1.4000 (+2.19%)
Ocugen Announces that the U.S. Food and Drug Administration Has Granted OCU410 Regenerative Medicine Advanced Therapy (RMAT) Designation for Treatment of Geographic Atrophy, Secondary to Dry Age-Related Macular Degeneration

RMAT designation is intended to help expedite development of new regenerative medicines that have potential to treat serious medical conditions with significant unmet need The designation could accelerate...

OCGN : 1.4000 (+2.19%)
Ocugen to Host Conference Call on Thursday, August 6 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2026 Financial Results

MALVERN, Pa., July 28, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that it...

OCGN : 1.4000 (+2.19%)
Ocugen, Inc. Announces Binding Term Sheet with Roots Pharmaceutical to License OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North Africa

Cumulative sales milestones up to $255 million and modest upfront/near-term development milestones Royalties equaling 22% of net sales Ocugen to manufacture and supply OCU400 MALVERN, Pa.,...

OCGN : 1.4000 (+2.19%)
Ocugen to Participate in Upcoming July Industry Conferences

MALVERN, Pa., July 01, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the...

OCGN : 1.4000 (+2.19%)
Ocugen to Participate in Upcoming June Investor and Industry Conferences

MALVERN, Pa., June 02, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the...

OCGN : 1.4000 (+2.19%)
Ocugen, Inc. Announces Closing for $130.0 Million of 6.75% Convertible Senior Notes

MALVERN, Pa., May 14, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced the closing...

OCGN : 1.4000 (+2.19%)

Business Summary

Ocugen Inc. is a clinical stage biopharmaceutical company. It is focused on discovering, developing and commercializing therapies which address rare and underserved eye diseases. The company's product pipeline consists of OCU400, OCU300, OCU100 and OCU200 which are in clinical stage. Ocugen Inc., formerly...

See More

Key Turning Points

3rd Resistance Point 1.4633
2nd Resistance Point 1.4167
1st Resistance Point 1.3933
Last Price 1.4000
1st Support Level 1.3233
2nd Support Level 1.2767
3rd Support Level 1.2533

See More

52-Week High 2.7250
Fibonacci 61.8% 2.0584
Fibonacci 50% 1.8525
Fibonacci 38.2% 1.6466
Last Price 1.4000
52-Week Low 0.9800

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.